What ChondroFiller costs in the UK

ChondroFiller injection pricing in the UK follows a fixed three-tier structure based on how many boxes of the collagen scaffold are required for a given defect:

| Boxes required | Guide cost | |---|---| | One box | £3,000 | | Two boxes | £5,500 | | Three boxes | £8,000 |

In the most complex multi-box cases, costs may reach approximately £9,800 at the upper end.

For most patients presenting with a focal cartilage defect, one box is sufficient — placing the majority at the £3,000 entry tier. The number of boxes is determined at assessment by the size of the defect: one box covers lesions of roughly 3 cm², two boxes extend to around 4.5 cm², and three boxes to approximately 6 cm².

Pricing is joint-agnostic. The same three tiers apply whether the joint being treated is the knee, hip, ankle, shoulder, elbow, or wrist — the scaffold volume needed, not the joint site, drives the cost.

All figures above are guide costs. Patients should confirm current pricing directly with the treating clinic at their initial consultation, as individual clinical circumstances may affect the final treatment plan.

What is included in the price

Each of the three tiers quoted above covers the full episode of care. Across published UK pricing sources, no separately billed extras have been documented — the following components are bundled into a single fee:

• Specialist consultation — the pre-procedure assessment to confirm suitability and determine the number of boxes needed
• Real-time ultrasound guidance — image-guided placement of the scaffold throughout the appointment
• The ChondroFiller collagen scaffold — the CE Class III product itself, imported under prescription
• Intravenous antibiotic cover — administered at the time of treatment
• Six-week follow-up appointment — to review the treated joint

The procedure is carried out as an outpatient, ultrasound-guided injection appointment — not a theatre admission or surgical procedure. There is no general anaesthetic, no incision, and no hospital stay involved.

Bundled pricing makes fair comparison with private surgical alternatives more straightforward: the surgical quotes patients receive typically cover procedure costs alone, with anaesthetic fees, implants, and aftercare often billed separately. When comparing options, it is worth establishing what each quoted figure actually includes.

How defect size determines which tier applies

Those three size thresholds — roughly 3 cm², 4.5 cm², and 6 cm² for one, two, and three boxes respectively — are not arbitrary. They reflect the volume of collagen scaffold needed to fill a lesion of each area and provide the structural support for the body's own repair process to take hold. Defect surface area is the sole volume driver; joint location plays no part in the calculation.

How the size is established

Defect size is typically assessed on MRI before the consultation. The imaging report quantifies the lesion in square centimetres; the treating specialist reviews this at the initial appointment and uses it to confirm which box count applies. Patients who already have MRI images from an earlier scan or referral are generally advised to bring them.

Because most focal cartilage lesions are smaller defects, the one-box tier is the most frequently applicable outcome in clinical practice — which is why £3,000 is cited as the common starting point rather than the exception.

What this means before your appointment

Patients cannot determine their own tier in advance. Until the MRI is reviewed and the lesion area confirmed at a specialist assessment, the applicable box count — and therefore the guide cost — remains open. The most direct question to raise at that first appointment is: what does the MRI show about defect size, and which tier does that indicate for me?

Prices in Germany, Austria, and Lithuania

For patients who have explored cross-border options, private clinics in Germany and Austria typically charge approximately €2,500–€4,500 per ChondroFiller procedure. Lithuania, which actively markets itself as a medical-tourism destination for the treatment, offers all-inclusive starter packages from around €3,350.

Those figures are generally lower than equivalent UK guide costs. One reason is proximity to supply: ChondroFiller is manufactured by Meidrix Biomedicals GmbH in Germany and distributed locally across continental markets, which reduces the importation and prescription logistics that add to the UK cost.

It is worth being clear about what the available data does and does not cover. Pricing information has been recovered for three countries — Germany, Austria, and Lithuania. No independent figures from other European nations were identified; the range above should be read as a partial picture, not a comprehensive European benchmark.

On the question of medical tourism specifically, the headline saving can narrow once travel, accommodation, and return visits for follow-up are factored in. A follow-up appointment at six weeks is a standard part of the treatment episode; patients travelling for care will need to plan for that logistics cost as well. Neither cross-border nor domestic treatment is inherently preferable — the practical and clinical balance depends on individual circumstances and is worth discussing with a specialist before any decision is made.

NHS funding, private insurance, and self-pay

ChondroFiller is not currently available through the NHS, and no active commissioning pathway or public-funding application is in progress. CE Class III regulatory approval — which ChondroFiller holds across more than 20 European countries — is a market-access decision, entirely separate from any reimbursement decision; approval does not trigger funding. The same logic applies on the continent: German statutory Krankenkasse plans and Austrian statutory insurers do not currently reimburse the procedure.

For the majority of patients, the practical default is therefore self-pay at the guide costs already covered.

Private insurance — a genuine route worth checking

The one meaningful exception is UK private medical insurance. Some policies from Bupa, Aviva, and WPA may cover ChondroFiller procedures. Clinics bill using two CCSD codes: W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy) — the standardised reference codes that appear in insurer policy documents and pre-authorisation forms.

Coverage is not guaranteed and varies by policy tier and individual circumstances. Patients with private cover are advised to contact their insurer before booking a consultation, ask specifically about pre-authorisation in writing, and confirm that both codes are recognised under their plan. Verbal assurances are not a reliable substitute — written pre-authorisation is the only secure confirmation if a claim is later disputed.

How ChondroFiller cost compares to cartilage repair surgery

Placed against the broader menu of cartilage repair options, ChondroFiller's guide costs sit at the lower end of the private treatment spectrum — though the comparison requires some care.

Private general cartilage repair surgery in the UK typically runs £7,000–£14,000. MACI (matrix-induced autologous chondrocyte implantation) sits considerably higher, at £30,000–£40,000 or more. At the £3,000 entry tier, ChondroFiller also undercuts private microfracture, which is generally quoted at £4,500–£7,000. That said, microfracture and ChondroFiller are not equivalent procedures: microfracture stimulates fibrocartilage, which is structurally weaker than the hyaline-like tissue ChondroFiller is designed to support through acellular matrix-induced chondrogenesis.

The cost difference between ChondroFiller and surgical alternatives also partly reflects a difference in delivery pathway. ChondroFiller is administered as an ultrasound-guided outpatient injectable scaffold procedure — no theatre admission, no general anaesthetic, no surgical wound recovery. Theatre-based operations carry the overhead of that setting.

One funding asymmetry deserves plain acknowledgement. MACI is NICE-approved and may be available on the NHS at no direct patient cost for eligible patients. ChondroFiller remains entirely self-pay or privately insured. A patient who might qualify for MACI on the NHS should discuss that option with their specialist before committing to any self-funded route.

Price alone should not determine which pathway is appropriate. Defect characteristics, joint location, prior treatment history, and overall clinical picture all factor into a specialist's assessment. Search MSK lists specialists across the UK who offer ChondroFiller — filter by region and specialty to find one suited to your situation.